Navigation Links
Study shows that major Alzheimer's risk gene causes alterations in shapes of brain protein deposits
Date:7/14/2010

Researchers at Mount Sinai School of Medicine have used a newly discovered class of biomarkers to investigate the possibility that the shape of brain protein deposits is different in people with Alzheimer's who have the highest-risk gene type than in those with the condition who have a neutral risk gene type. The study is being presented July 14 at the 2010 Alzheimer's Association International Conference on Alzheimer's Disease in Honolulu, Hawaii.

Sam Gandy, MD, PhD, the Mount Sinai Professor in Alzheimer's Disease Research, Professor of Neurology and Psychiatry, and Associate Director of the Alzheimer's Disease Research Center at Mount Sinai School of Medicine, led the study. Mount Sinai labs led by Patrick R. Hof, MD, Regenstreif Professor of Neuroscience and Vice-Chair for Translational Neuroscience of the Department of Neuroscience and Dara L. Dickstein, PhD, Assistant Professor, Neuroscience also collaborated on the study.

Apolipoprotein E (APOE) is a gene containing instructions needed to make a protein that helps carry cholesterol in the bloodstream. The APOE gene, which comes in several different forms, is related to increased risk of developing Alzheimer's disease. People with APOE ε4/ε4 gene type have the highest risk of developing the disease and people with APOE ε3/ε3 have a neutral risk. Discovering the important mechanisms underlying how APOE ε4/ε4 increases Alzheimer's risk has been one of the most vexing mysteries facing Alzheimer's researchers for over a decade.

Luminescent conjugated oligothiophenes (LCOs) or luminescent conjugated polymers (LCPs), the newly discovered class of biomarkers, can stick to protein structures in the body and emit colors reflecting the different shapes or forms of the proteins. Among other uses, LCPs/LCOs are currently being employed in test tubes, animal models, and autopsied Alzheimer's brains to study the structure of proteins deposits caused by the disease. The new markers bind to the two well-established hallmarks of Alzheimer's beta amyloid plaques and tau tangles and glow different colors depending on which forms of the deposits they "stick" to (e.g., plaques often "glow" orange, while tangles "glow" yellowish green).

In the study, frozen brain sections from people who died with Alzheimer's were stained using two LCPs/LCOs: pentamer formyl thiophene acetic acid (pFTAA) and polythiophene acetic acid (PTAA). Using PTAA, the researchers observed that Alzheimer patients with APOE ε4/ε4 gene type had core and cerebrovascular amyloid of different shapes, while in people with APOE ε3/ε3, the two amyloid structures had the same shape. Using pFTAA revealed that tau tangle densities in ε4/ε4 Alzheimer patients that were apparently greater than those with ε3/ε3.

"The findings support our hypothesis that APOE genotype changes amyloid structure," Dr. Gandy said. "This is important because the different shapes might respond differently to treatments that attempt to clear amyloid deposits from the brain. We already know, for example, that APOE ε4/ε4 patients respond less well to anti-amyloid antibody with bapineuzumab."


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. U of M study finds fast food chains have significantly decreased trans fats in cooking oils
2. Researchers study relationship of oral cancers and periodontal disease
3. Interferon might help asthma patients breathe easier, UT Southwestern study suggests
4. Whisker stimulation prevents strokes in rats, UCI study finds
5. University of Mississippi Medical Center to lead in nationwide NIH-funded Alzheimers study
6. Study shows universal surveillance for MRSA significantly decreased HAIs at PCMH
7. Study finds lifelong doubling in death risk for men who are obese at age 20 years
8. Arsenic shows promise as cancer treatment, Stanford study finds
9. Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma
10. Mayo Clinic study finds apathy and depression predict progression from mild cognitive impairment
11. New study suggests tart cherry juice can be a natural solution for insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare professionals gained ... was held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , ... of independent hearing healthcare providers to help them stay ahead in the industry. At ...
(Date:5/26/2017)... ... May 26, 2017 , ... Mediaplanet is proud to ... campaign in USA Today, which will educate readers on how to take care of ... a large focus is placed on melanoma. Dancing with the Stars professional, Witney Carson, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs ... on May 30th and 31st at The Four Seasons Hotel Boston. , ... the life sciences, offering exclusive access to key decision makers who influence deal ...
(Date:5/26/2017)... ... ... Amir Qureshi, MD is the first physician in Arkansas to implant Nuvecta’s ... Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for chronic ... introduce the most powerful SCS system and the only stretchable lead on the market. ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community ... healthiest seniors are located in the Midwest. With the average cost of healthcare rising ... are concerned with both the quality and affordability of where they live. An annual ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... , May 17, 2017  Bayer announced today ... portfolio will be presented at the 53 rd ... (ASCO), taking place June 2-6 in Chicago ... at ASCO span prostate, colorectal, liver and thyroid cancers, ... from the Phase II CHRONOS-1 trial of copanlisib in ...
(Date:5/10/2017)... Hologic, Inc. (Nasdaq: HOLX ) announced today ... ended April 1, 2017 .   GAAP diluted earnings ... the prior year period as the sale of the ... non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue of ... terms.  Excluding the effects of blood screening and the ...
(Date:5/9/2017)... Ind. , May 9, 2017 Zimmer ... leader in musculoskeletal healthcare, today announced it has earned ... Employers of 2017" list. The Company was ranked among ... of Large Employers and Healthcare Equipment and Services. ... employers based on an anonymous, independent survey of over ...
Breaking Medicine Technology: